A phase I trial of UCN-01 and prednisone in patients with refractory solid tumors and lymphomas
- 6 November 2009
- journal article
- clinical trial-report
- Published by Springer Science and Business Media LLC in Cancer Chemotherapy and Pharmacology
- Vol. 65 (2), 383-389
- https://doi.org/10.1007/s00280-009-1154-y
Abstract
Purpose UCN-01 potently inhibits protein kinase C, phosphatidylinositide-dependent kinase-1, and checkpoint kinase 1, which are involved in regulating cell cycle progression. We designed a phase I study to determine the maximum tolerated dose (MTD) of UCN-01 with prednisone in patients with advanced malignancies. Methods UCN-01 was administered as a continuous intravenous infusion over 72 h in cycle 1 and 36 h in subsequent cycles. Prednisone was given orally at 60 mg/m2 per day for five consecutive days within each 28-day cycle. Standard dose escalation was employed, and MTD was defined as the dose at which no more than one of six patients experienced a dose-limiting toxicity (DLT). Plasma pharmacokinetics of UCN-01 were assessed. Results Fifteen patients received a total of 55 courses of treatment. The MTD and the recommended phase II dose of UCN-01 in this combination is 72 mg/m2 total dose over 72 h for cycle 1 followed by 36 mg/m2 per cycle over 36 h. All patients experienced hyperglycemia but responded to insulin treatment. Hypophosphatemia was a DLT in two patients. There were no cumulative toxicities. No objective responses were observed, but five patients had stable disease, including two patients with lymphoid malignancies who had prolonged disease stabilizations. UCN-01 has a long terminal half-life and low clearance; there was wide inter-patient variability in peak concentrations. Conclusion UCN-01 can be safely administered in combination with prednisone without unacceptable toxicity. The prolonged stable disease in two patients with lymphoid malignancies is a proof of principle for the evaluation of cyclin-dependent kinase inhibitors in oncology.Keywords
This publication has 28 references indexed in Scilit:
- CDK inhibitors in cancer therapy: what is next?Trends in Pharmacological Sciences, 2008
- Phase I and Pharmacokinetic Study of 7-Hydroxystaurosporine and Carboplatin in Advanced Solid TumorsClinical Cancer Research, 2007
- Phase I and pharmacokinetic study of UCN-01 in combination with irinotecan in patients with solid tumorsCancer Chemotherapy and Pharmacology, 2007
- Cyclin-Dependent Kinase Pathways As Targets for Cancer TreatmentJournal of Clinical Oncology, 2006
- The Cyclin-Dependent Kinase Inhibitor UCN-01 Plus Cisplatin in Advanced Solid Tumors: A California Cancer Consortium Phase I Pharmacokinetic and Molecular Correlative TrialClinical Cancer Research, 2005
- Phase I Trial of the Cyclin-Dependent Kinase Inhibitor and Protein Kinase C Inhibitor 7-Hydroxystaurosporine in Combination With Fluorouracil in Patients With Advanced Solid TumorsJournal of Clinical Oncology, 2005
- Interference with PDK1-Akt survival signaling pathway by UCN-01 (7-hydroxystaurosporine)Oncogene, 2002
- A high-performance liquid chromatography method using ultraviolet and fluorescence detection for the quantitation of UCN-01, 7-hydroxystaurosporine, from human plasma and salivaBiomedical Chromatography, 2000
- New Guidelines to Evaluate the Response to Treatment in Solid TumorsJNCI Journal of the National Cancer Institute, 2000
- The inhibitory effect of staurosporine on insulin action is prevented by okadaic acid. Evidence for an important role of serine/threonine phosphorylation in eliciting insulin-like effectsBiochimica et Biophysica Acta (BBA) - Molecular Cell Research, 1996